Pharmaceutical composition or drug delivery system as well as preparation method and application thereof
By combining PLGA nanoparticles with red blood cells and modifying them with blood type glycoprotein A antibodies, effective targeted drug delivery is achieved, solving the problems of low drug delivery efficiency and major toxic side effects in the prior art, and significantly improving the lungs The treatment effect of the disease.
Patent Information
- Application Number
- CN202310511850.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-08
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-05-08
Smart Images

Figure CN118903458A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a pharmaceutical composition or a drug delivery system and a preparation method and use thereof. The pharmaceutical composition or drug delivery system can target the lungs, effectively improve the lung delivery efficiency of the drug, and can be used to treat diseases such as acute lung injury, pulmonary fibrosis, and pulmonary tuberculosis. Background Art
[0002] Globally, the morbidity and mortality of acute or chronic lung-related diseases remain high. In addition to the efficacy of the drug itself, drug metabolism properties and other factors, the efficiency of the drug delivery system is a key influencing factor in the effectiveness of drug treatment of lung-related diseases. Traditional drug delivery technology lacks targeting, has low drug delivery efficiency and limited clinical efficacy; in addition, the systemic distribution of drugs is prone to increase the risk of toxic side effects.
[0003] Targeted drug delivery systems can greatly improve the efficiency of drug delivery, increase the local drug concentration of target organs / tissues, and reduce systemic drug exposure and toxic side effects while enhancing the efficacy. At present, lung-targeted drug delivery technologies can be mainly divided into two categories. One is lung inhalation drug delivery technology. However, drugs that are unstable in atomization or easily inactivated by proteases in the airways are not suitable for lung inhalation administration. At the same time, lung inhalation administration is not suitable for severe and critically ill patients who have already developed symptoms of respiratory distress and cannot breathe independently. The other category is mainly based on molecular target-based lung-targeted drug delivery technology. However, in addition to being expressed on lung-related cells, most of these molecular targets are also expressed on the same type or other types of cells in other tissues and organs. This will lead to non-targeted delivery of drugs and reduce the efficiency of targeted delivery. Secondly, certain targets or cells expressing targets (such as macrophages) play an important role in maintaining the normal function of the body, and targeting such cells may affect their normal function. In addition, complex endogenous substance interference and barrier effects in the body result in that molecular target-based lung-targeted drug delivery technology often failing to fully play its role in identifying targets in the body, and sometimes even being treated as exogenous toxins and excreted from the body, unable to reach the lung lesions as designed and exert the expected therapeutic effect. Summary of the invention
[0004] In one aspect, the present invention provides a pharmaceutical composition or drug delivery system comprising:
[0005] (1) first drug-loaded PLGA nanoparticles and red blood cells, or
[0006] (2) The second drug-loaded PLGA nanoparticles have their surfaces modified with glycophorin A antibodies.
[0007] In certain embodiments, the red blood cells are derived from the blood of a subject.
[0008] In certain embodiments, the pharmaceutical composition or drug delivery system is administered to the subject by intravenous injection.
[0009] In certain embodiments, the first drug-loaded PLGA nanoparticles are bound to erythrocytes and loaded onto the surface of erythrocytes.
[0010] In certain embodiments, the second drug-loaded PLGA nanoparticles bind to red blood cells in a subject after intravenous injection and are loaded onto the surface of the red blood cells.
[0011] In certain embodiments, the pharmaceutical composition or drug delivery system is a lung-targeted pharmaceutical composition or drug delivery system.
[0012] In certain embodiments, the first drug-loaded PLGA nanoparticles or the second drug-loaded PLGA nanoparticles contain PLGA, and the ratio of lactic acid to glycolic acid is 10:90 to 90:10, preferably 10:90 to 50:50, and more preferably 25:75.
[0013] In certain embodiments, the first drug-loaded PLGA nanoparticles or the second drug-loaded PLGA nanoparticles contain PLGA with a molecular weight of 5,000-100,000, preferably 10,000-50,000.
[0014] In certain embodiments, the Zeta potential of the first drug-loaded PLGA nanoparticles is -50 to +50 mV, preferably -30 to 0 mV, and more preferably -30 to -15 mV.
[0015] In certain embodiments, the Zeta potential of the second drug-loaded PLGA nanoparticles is -50 to +50 mV, preferably -30 to +30 mV, and more preferably about 0 mV.
[0016] In certain embodiments, the particle size of the first drug-loaded PLGA nanoparticles is 5 to 1000 nm, preferably 100 to 500 nm, and more preferably 150 to 400 nm.
[0017] In certain embodiments, the second drug-loaded PLGA nanoparticles, before being modified with glycophorin A antibody, have a particle size of 5 to 1000 nm, preferably 100 to 500 nm, and more preferably 150 to 400 nm.
[0018] In certain embodiments, the pharmaceutical composition or drug delivery system further comprises a pharmaceutically acceptable carrier, such as physiological saline.
[0019] In certain embodiments, the drug loaded by the first drug-loaded PLGA nanoparticles or the second drug-loaded PLGA nanoparticles is a drug that can treat lung-related diseases, such as methylprednisolone, pirfenidone, or cepharanthin.
[0020] Another aspect of the present invention provides a method for preparing the pharmaceutical composition or drug delivery system of the present invention, comprising:
[0021] 1) Add the drug to the organic solution of PLGA and perform ultrasonic emulsification;
[0022] 2) Optionally, adding the product obtained in 1) to a surfactant solution (e.g., aqueous solution) and stirring;
[0023] 3) removing the organic solvent from the product obtained in 1) or 2), separating and washing to obtain the first drug-loaded PLGA nanoparticles;
[0024] 4) combining the first drug-loaded PLGA nanoparticles with red blood cells, or co-incubating the first drug-loaded PLGA nanoparticles with glycophorin A antibodies to obtain second drug-loaded PLGA nanoparticles whose surfaces are modified with glycophorin A antibodies.
[0025] In certain embodiments, the surfactant solution is selected from the group consisting of: poloxamer (eg, poloxamer P188), polyvinyl alcohol, cetyltrimethylammonium bromide, and any combination thereof.
[0026] Another aspect of the present invention also provides a method for delivering the pharmaceutical composition or drug delivery system of the present invention, comprising:
[0027] 1) Collecting red blood cells from the subject;
[0028] 2) co-incubating the first drug-loaded PLGA nanoparticles resuspended in physiological saline with red blood cells, so that the first drug-loaded PLGA nanoparticles bind to the red blood cells and are loaded on the surface of the red blood cells;
[0029] 3) delivering the product obtained in 2) to the subject intravenously, or
[0030] Another aspect of the present invention provides another method for delivering the pharmaceutical composition or drug delivery system of the present invention, comprising: directly delivering the second drug-loaded PLGA nanoparticles to a subject intravenously.
[0031] Another aspect of the present invention also provides use of the pharmaceutical composition or drug delivery system of the present invention in the preparation of drugs for treating acute lung injury, pulmonary fibrosis, and pulmonary tuberculosis.
[0032] In certain embodiments, the subject of the present invention is a mammal, including bovines, equines, ovines, porcines, canines, felines, rodents, primates, etc., for example, humans, cats, dogs, horses, cows, sheep or pigs.
[0033] definition
[0034] Unless otherwise defined below, the meanings of all technical terms and scientific terms used herein are intended to be the same as those generally understood by those skilled in the art. Reference to the technology used herein is intended to refer to the technology generally understood in the art, including those changes in technology or replacement of equivalent technology that are obvious to those skilled in the art. Although it is believed that the following terms are well understood by those skilled in the art, the following definitions are still set forth to better explain the present invention.
[0035] As used herein, the terms "comprises," "comprising," "having," "containing," or "involving," and other variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps.
[0036] As used herein, the term "about" means within what one of ordinary skill in the art considers to be an acceptable standard error for the stated value, e.g., ±0.05, ±0.1, ±0.2, ±0.3, ±1, ±2, or ±3, etc. Unless otherwise apparent from the context, all numerical values provided herein are modified by the term "about."
[0037] As used herein, the term "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle with which a therapeutic agent is administered and which is, within the scope of sound medical judgment, suitable for contact with the tissues of humans and / or other animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit / risk ratio.
[0038] Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition or drug delivery system of the present invention include, but are not limited to, sterile liquids, such as water, physiological saline, and aqueous glucose solution, etc., in particular, various liquids suitable for injection.
[0039] The dosage regimen may be adjusted to provide the best desired response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dosage may be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering the composition or supervising the administration of the composition.
[0040] The amount of the drug of the present invention administered will depend on the severity of the individual, disease or condition treated, the rate of administration, the disposal of the compound and the judgment of the prescribing physician. Generally speaking, the effective dose is about 0.0001 to about 100 mg per kg body weight per day, for example, about 0.01 to about 10 mg / kg / day (single or divided administration). In some cases, the dosage level not higher than the lower limit of the aforementioned range may be sufficient, and in other cases, a larger dose may still be used without causing any harmful side effects, provided that the larger dose is first divided into several smaller doses to be administered throughout the day.
[0041] As used herein, unless otherwise indicated, the terms "treat," ... BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 is a transmission electron microscopy photograph of methylprednisolone-PLGA nanoparticles prepared in Example 1;
[0043] Figure 2 is a transmission electron microscopy photograph of methylprednisolone-PLGA nanoparticles prepared in Example 2;
[0044] Figure 3 is a transmission electron microscopy photograph of methylprednisolone-PLGA nanoparticles prepared in Example 3;
[0045] Figure 4 is a transmission electron microscopy photograph of methylprednisolone-PLGA nanoparticles prepared in Example 4;
[0046] Figure 5 It is a scanning electron microscope photograph of the methylprednisolone-PLGA nanoparticle-erythrocyte complex prepared in Example 10, and the upper left, upper right, lower left, and lower right are the complexes of methylprednisolone-PLGA nanoparticles and erythrocytes prepared in Example 1, Example 2, Example 3, and Example 4, respectively;
[0047] Figure 6 is the adhesion rate of the nanoparticles prepared in Example 1, Example 2, Example 3, Example 4 and Example 7 to red blood cells;
[0048] Figure 7 The drug concentration distribution in the lung and liver of rats after intravenous administration of the nanoparticles prepared in Examples 1, 2, 3, 4 and 7 and the methylprednisolone-PLGA nanoparticle-erythrocyte complex prepared in Example 10;
[0049] Figure 8The drug concentration distribution of the cephalaenoside-PLGA nanoparticles and the glycophorin A antibody-modified cephalaenoside-PLGA nanoparticles prepared in Example 6 in the lungs and livers of rats after intravenous administration;
[0050] Fig. 9 The distribution of fluorescent signals in the lungs and livers of mice after intravenous injection of Cy7.5-NP or RBC-Cy7.5-NP. DETAILED DESCRIPTION
[0051] The present invention will be described below in conjunction with the embodiments and test examples. It should be understood that the following embodiments and test examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. In the embodiments and test examples, if specific conditions are not specified, they are carried out according to conventional conditions or conditions recommended by the manufacturer, and if the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0052] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0053] Example 1: Preparation of methylprednisolone-PLGA nanoparticles
[0054] Weigh 30 mg of PLGA (lactic acid and glycolic acid ratio of 75:25, molecular weight of 15000) and dissolve it in 1 ml of dichloromethane. Weigh 3 mg of methylprednisolone and add it to the above PLGA solution to dissolve it. Pour the methylprednisolone-PLGA solution drop by drop into 10 ml of 1% poloxamer P188 aqueous solution at a rate of 8 mL / h. Stir while adding dropwise at a stirring speed of 800 r / min. After the addition is completed, place it in a fume hood and continue stirring for 6 hours to remove the organic solvent. Centrifuge at 14000 r / min for 20 minutes and wash three times. The particle size of the prepared methylprednisolone-PLGA nanoparticles is 205.14 nm, the Zeta potential is -25.36 mV, and the transmission electron microscope photo is shown in Figure 1 .
[0055] Example 2: Preparation of methylprednisolone-PLGA nanoparticles
[0056] Weigh 30 mg of PLGA (lactic acid and glycolic acid ratio of 50:50, molecular weight of 15000) and dissolve it in 1 ml of dichloromethane. Weigh 3 mg of methylprednisolone and add it to the above PLGA solution to dissolve it. Pour the methylprednisolone-PLGA solution drop by drop into 10 ml of 1% poloxamer P188 aqueous solution at a rate of 8 mL / h. Stir while adding dropwise at a stirring speed of 800 r / min. After the addition is completed, place it in a fume hood and continue stirring for 6 hours to remove the organic solvent. Centrifuge at 14000 r / min for 20 minutes and wash three times. The particle size of the prepared methylprednisolone-PLGA nanoparticles is 201.39 nm, the Zeta potential is -20.65 mV, and the transmission electron microscope photo is shown in Figure 2 .
[0057] Example 3: Preparation of methylprednisolone-PLGA nanoparticles
[0058] Weigh 30 mg of PLGA (lactic acid and glycolic acid ratio of 25:75, molecular weight of 15000) and dissolve it in 1 ml of dichloromethane. Weigh 3 mg of methylprednisolone and add it to the above PLGA solution to dissolve it. Pour the methylprednisolone-PLGA solution dropwise into 10 ml of 1% poloxamer P188 aqueous solution at a rate of 8 mL / h. Stir while adding dropwise at a stirring speed of 800 r / min. After the addition is completed, place it in a fume hood and continue stirring for 6 hours to remove the organic solvent. Centrifuge at 14000 r / min for 20 minutes and wash three times. The particle size of the prepared methylprednisolone-PLGA nanoparticles is 203.57 nm, the Zeta potential is -17.28 mV, and the transmission electron microscope photo is shown in Figure 3 .
[0059] Example 4: Preparation of methylprednisolone-PLGA nanoparticles
[0060] Weigh 30 mg of PLGA (lactic acid and glycolic acid ratio of 10:90, molecular weight of 15000) and dissolve it in 1 ml of dichloromethane. Weigh 3 mg of methylprednisolone and add it to the above PLGA solution to dissolve it. Pour the methylprednisolone-PLGA solution drop by drop into 10 ml of 1% poloxamer P188 aqueous solution at a rate of 8 mL / h. Stir while adding dropwise at a stirring speed of 800 r / min. After the addition is completed, place it in a fume hood and continue stirring for 6 hours to remove the organic solvent. Centrifuge at 14000 r / min for 20 minutes and wash three times. The particle size of the prepared methylprednisolone-PLGA nanoparticles is 198.56 nm, the Zeta potential is -16.34 mV, and the transmission electron microscope photo is shown in Figure 4 .
[0061] Example 5: Preparation of Pirfenidone-PLGA Nanoparticles
[0062] Weigh 10 mg of pirfenidone and dissolve it in 0.5 mL of ultrapure water, add it dropwise to 10 ml of 10 mg / ml PLGA (lactic acid and glycolic acid ratio is 25:75, molecular weight is 30000) in dichloromethane solution, and ultrasonic emulsify for 30 seconds. Then add the obtained emulsion to 10 mL of 5% PVA (polyvinyl alcohol) aqueous solution, ultrasonic emulsify for 30 seconds, continue stirring for 4 hours to volatilize the organic solvent. Centrifuge at 14000 r / min for 20 minutes to collect nanoparticles.
[0063] Example 6: Preparation of Cephalaenopsis-PLGA Nanoparticles
[0064] Weigh 20 mg PLGA (lactic acid and glycolic acid ratio of 25:75, molecular weight of 10000) and 4 mg cephalothin and dissolve in 4 ml acetone. Add the cephalothin-PLGA solution drop by drop into 20 ml aqueous solution containing 1% poloxamer P188, stirring while adding, the stirring speed is 800 r / min. After the addition is completed, place it in a fume hood and continue stirring for 6 hours to remove the organic solvent. Centrifuge at 14000 r / min for 20 minutes and wash three times. The prepared cephalothin-PLGA nanoparticles have a particle size of 165.34 nm and a Zeta potential of -26.37 mV.
[0065] Weigh 20 mg PLGA (lactic acid and glycolic acid ratio of 25:75, molecular weight of 10000) and 4 mg cephalothin and dissolve in 4 ml acetone. Add the cephalothin-PLGA solution drop by drop into 20 ml of an aqueous solution containing 1% poloxamer P188 and 0.005% CTAB (hexadecyltrimethylammonium bromide), stirring while adding, the stirring speed is 800 r / min. After the addition is completed, place it in a fume hood and continue stirring for 6 hours to remove the organic solvent. Centrifuge at 14000 r / min for 20 minutes and wash three times. The prepared cephalothin-PLGA nanoparticles have a particle size of 169.12 nm and a Zeta potential of +21.61 mV.
[0066] Weigh 20 mg PLGA (lactic acid and glycolic acid ratio of 25:75, molecular weight of 10000) and 4 mg cephalothin and dissolve in 4 ml acetone. Add the cephalothin-PLGA solution drop by drop into 20 ml of an aqueous solution containing 1% poloxamer P188 and 0.0027% CTAB. Stir while adding dropwise at a speed of 800 r / min. After the addition is complete, place in a fume hood and continue stirring for 6 hours to remove the organic solvent. Centrifuge at 14000 r / min for 20 minutes and wash three times. The prepared cephalothin-PLGA nanoparticles have a particle size of 160.89 nm and a Zeta potential of -0.0057 mV.
[0067] The above three different charged nanoparticles (0.01 mol) were resuspended in PBS buffer, and 0.1 mol of EDC and 0.3 mol of N-hydroxysuccinimide (NHS) were added, respectively, and incubated at 4°C for 30 minutes. After centrifugation and washing, the nanoparticles were resuspended in PBS buffer, and glycophorin A antibody (GPAA, 0.01 mol, purchased from ThermoFisher, 14-5921-82) was added, and incubated at 4°C overnight. Centrifugation and washing gave glycophorin A antibody-modified cephalothin-PLGA nanoparticles.
[0068] Example 7: Preparation of methylprednisolone-PLGA nanoparticles modified with glycophorin A antibody
[0069] Take an appropriate amount (0.01 mol) of the methylprednisolone-PLGA nanoparticles prepared in Example 3 and resuspend them in PBS buffer, add 0.1 mol of carbodiimide (EDC) and 0.3 mol of N-hydroxysuccinimide (NHS), respectively, and incubate at 4°C with shaking for 30 minutes. After centrifugal washing, the nanoparticles are resuspended in PBS buffer, and glycophorin A antibody (GPAA, 0.01 mol) is added, and incubated at 4°C with shaking overnight. Centrifugal washing gives glycophorin A antibody-modified methylprednisolone-PLGA nanoparticles (GPAA-methylprednisolone-PLGA).
[0070] Example 8: Preparation of Pirfenidone-PLGA Nanoparticles Modified with Glycophorin A Antibody
[0071] Take an appropriate amount (0.01 mol) of the pirfenidone-PLGA nanoparticles prepared in Example 5 and resuspend them in PBS buffer, and add 0.1 mol of carbodiimide (EDC) and 0.3 mol of N-hydroxysuccinimide (NHS) respectively. Incubate at 4°C with shaking for 30 minutes. After centrifugal washing, resuspend the nanoparticles in PBS buffer, add glycophorin A antibody (GPAA, 0.01 mol), and incubate at 4°C with shaking overnight. Centrifugal washing gives pirfenidone-PLGA nanoparticles modified with glycophorin A antibody.
[0072] Example 9: Preparation of packed red blood cells
[0073] Collect whole blood in a sodium heparin vacuum tube, centrifuge at 1300×g to remove the supernatant and the middle white blood cells, platelets, etc., add 4 times the volume of sterile saline solution to the red blood cells in the lower layer and mix gently, centrifuge at 850×g for 5 minutes and wash three times. After removing the supernatant, the washed packed red blood cells are obtained and placed in a 4°C refrigerator for use.
[0074] Example 10: Preparation of methylprednisolone-PLGA nanoparticle-erythrocyte complex
[0075] Take 200 μL of the packed red blood cells prepared in Example 9, add the methylprednisolone-PLGA nanoparticle solution prepared in Example 1 or Example 2 or Example 3 or Example 4 (equivalent to 800 μg of PLGA) resuspended in sterile saline, and incubate at 37°C for 30 min. Centrifuge at 100 g for 5 min, remove the supernatant, and wash three times with sterile saline to obtain the obtained complex. The scanning electron microscopy photograph of the obtained complex is shown in Figure 5 .
[0076] Example 11: Preparation of fluorescent dye cyt7.5-PLGA nanoparticles
[0077] Weigh 30 mg PLGA (lactic acid and glycolic acid ratio of 75:25, molecular weight of 15000) and 1 mg fluorescent dye cyt7.5 and dissolve them in 1 ml acetone. Add the above solution drop by drop at a speed of 10 mL / h into 10 ml 1% poloxamer P188 aqueous solution, stirring at a stirring speed of 800 r / min. After the addition is completed, place it in a fume hood and continue stirring for 6 hours to remove the organic solvent. Centrifuge at 14000 r / min for 20 minutes and wash three times.
[0078] Test Example 1: Adhesion rate of nanoparticles to red blood cells
[0079] Test method:
[0080] Take 200 μL of the packed red blood cells prepared in Example 9, add the GPAA-methylprednisolone-PLGA nanoparticle solution prepared in Example 7 (equivalent to 800 μg of PLGA) resuspended in sterile saline, and incubate at 37°C for 30 min. Centrifuge at 100 g for 5 min, take 200 μL of the suspension before centrifugation and after centrifugation washing, and add 800 μL of acetonitrile to each. Ultrasonic treatment for 1 min, vortex mixing for 3 min. The methylprednisolone content in the above samples was determined by HPLC, and the methylprednisolone content in the sample before centrifugation was recorded as W. 总药量 The methylprednisolone content in the sample after centrifugation and washing is recorded as W RBC . According to the adhesion rate of red blood cells = W RBC / W 总药量 *100% was used to calculate the adhesion rate of nanoparticles to red blood cells.
[0081] The suspensions of methylprednisolone-PLGA nanoparticles and erythrocytes after incubation at 37° C. before centrifugation and after centrifugal washing in Example 10 were taken separately, and the adhesion rate of the nanoparticles to erythrocytes was determined by the same method.
[0082] Test results:
[0083] The adhesion rates of the nanoparticles prepared in Example 1, Example 2, Example 3, Example 4 and Example 7 to red blood cells are as follows: Figure 6As shown. The adhesion rate of nanoparticles prepared by PLGA with a lactic acid and glycolic acid ratio of 75:25 (Example 1) to red blood cells is significantly higher than that of nanoparticles prepared by PLGA with a lactic acid and glycolic acid ratio of 50:50 (Example 2), 25:75 (Example 3) and 10:90 (Example 4). Figure 5 The scanning electron microscopy image of the nanoparticle-erythrocyte complex shows that the nanoparticles prepared with PLGA having a lactic acid:glycolic acid ratio of 75:25 have a stronger binding force with erythrocytes, and therefore show a higher erythrocyte adhesion rate. The electron microscopy image also shows that the number of nanoparticles prepared with PLGA having a lactic acid:glycolic acid ratio of 75:25 (Example 1) adhered to erythrocytes is significantly higher than that of the nanoparticles prepared with PLGA having a lactic acid:glycolic acid ratio of 50:50 (Example 2), 25:75 (Example 3) and 10:90 (Example 4).
[0084] The adhesion rate of glycophorin A antibody-modified methylprednisolone-PLGA nanoparticles (GPAA-methylprednisolone-PLGA) prepared in Example 7 to red blood cells was 88.27%, significantly higher than that in Example 3. The binding of GPAA to glycophorin A on the surface of red blood cells enhanced the binding efficiency of GPAA-methylprednisolone-PLGA to red blood cells.
[0085] Experimental Example 2: Lung targeting efficiency of nanoparticle-erythrocyte composition
[0086] Experimental method: 27 male SD rats were randomly divided into 9 groups. The methylprednisolone-PLGA nanoparticle solutions prepared in Example 1, Example 2, Example 3, and Example 4 (grouped and named NP1, NP2, NP3, and NP4) were administered by tail vein injection respectively; the GPAA-methylprednisolone-PLGA nanoparticles prepared in Example 7 (grouped and named NP7); and the complex formed by the methylprednisolone-PLGA nanoparticles and red blood cells prepared in Example 1, Example 2, Example 3, and Example 4 (Example 10, grouped and named RBC-NP1, RBC-NP2, RBC-NP3, and RBC-NP4). The dosage was 750 μg / rat (based on the active ingredient methylprednisolone). The rats were killed 2 hours after administration, and lung and liver samples were collected, weighed, and the methylprednisolone concentration in the tissues was determined.
[0087] The test results are shown in Figure 7 , showing the drug concentration distribution in the lungs and liver of rats after intravenous administration of the nanoparticles prepared in Examples 1, 2, 3, 4 and 7 and the methylprednisolone-PLGA nanoparticle-erythrocyte complex prepared in Example 10.
[0088] On the one hand, nanoparticle-erythrocyte complexes prepared with PLGA with different lactic acid and glycolic acid ratios have different lung targeting properties. RBC-NP3 (nanoparticle-erythrocyte complex prepared with PLGA with a lactic acid and glycolic acid ratio of 25:75) has a good lung-targeted drug delivery effect, and the drug concentration in the lung after 2 hours of administration is significantly higher than that of RBC-NP1 (nanoparticle-erythrocyte complex prepared with PLGA with a lactic acid and glycolic acid ratio of 75:25), RBC-NP2 (nanoparticle-erythrocyte complex prepared with PLGA with a lactic acid and glycolic acid ratio of 50:50) and RBC-NP4 (nanoparticle-erythrocyte complex prepared with PLGA with a lactic acid and glycolic acid ratio of 10:90). Moreover, RBC-NP3 can also significantly reduce the distribution of drugs in the liver. In contrast, the lung targeting effect of RBC-NP4 is poor, and its drug distribution in the liver is not significantly different from that of the single nanoparticles. It can be seen that the nanoparticle-erythrocyte complex prepared with PLGA with a lactic acid and glycolic acid ratio of 25:75 has excellent lung-targeted drug delivery ability, and its targeting performance is significantly better than that of the nanoparticle-erythrocyte complex prepared with PLGA with other lactic acid and glycolic acid ratios.
[0089] On the other hand, the methylprednisolone-PLGA nanoparticles modified with glycophorin A antibodies prepared in Example 7 have lung targeting performance comparable to that of RBC-NP3 after intravenous injection. Although the GPAA-methylprednisolone-PLGA nanoparticles are not incubated with red blood cells in vitro to prepare nanoparticle-erythrocyte complexes, they still have excellent lung targeting ability, and the drug concentration in the lungs after administration is significantly higher than that of the unmodified nanoparticle NP3. GPAA-methylprednisolone-PLGA nanoparticles can actively target red blood cells through GPAA, bind to glycophorin A on the surface of red blood cells, complete the nanoparticle-erythrocyte complex in vivo, and have lung targeting performance similar to that of nanoparticle-erythrocyte complexes prepared in vitro. Compared with the method of preparing nanoparticle-erythrocyte complexes in vitro and then reinfusing them, this method is simpler and more convenient, reduces the process of collecting blood cells and incubation, avoids the possible risk of blood cell contamination, and reduces the damage to red blood cells caused by the in vitro preparation process.
[0090] Experimental Example 3: Lung Targeting Efficiency of Nanoparticle-Red Blood Cell Complex
[0091] Experimental method: 18 male SD rats were randomly divided into 6 groups. The cephalaenoside-PLGA nanoparticle solution prepared in Example 6 (grouped and named NP+, NP-, NP0 according to the charge) and the cephalaenoside-PLGA nanoparticle solution modified with glycophorin A antibody (grouped and named GPAA-NP+, GPAA-NP-, GPAA-NP0 according to the charge) were respectively administered by tail vein injection, and the dosage was 900 μg / rat. The rats were killed 2h after administration, and lung and liver samples were collected, weighed, and the concentration of cephalaenoside in the tissues was determined.
[0092] The test results are shown in Figure 8 , showing the drug concentrations of cephalothin-PLGA nanoparticles and cephalothin-PLGA nanoparticles modified with glycophorin A antibodies prepared in Example 6 in the lungs and livers of rats after intravenous administration. The results showed that the nanoparticles that were not modified with glycophorin A antibodies were mainly taken up by the liver after intravenous injection, and the drug distribution concentration in the lungs was low. However, the distribution of uncharged neutral nanoparticles NP0 in the liver was lower than that of positively or negatively charged nanoparticles. The lung targeting performance of the nanoparticles modified with glycophorin A antibodies was significantly improved after intravenous injection, and the local drug concentration in the lungs was significantly higher than that of the nanoparticles that were not modified with glycophorin A antibodies. Moreover, the drug concentration in the lungs of the neutral nanoparticle group modified with glycophorin A antibodies was significantly higher than that of the charged nanoparticles modified with glycophorin A antibodies; while the drug concentration in the liver was significantly lower than that of the charged nanoparticles modified with glycophorin A antibodies.
[0093] Experimental Example 4: Lung Targeting of Nanoparticle-Red Blood Cell Composition
[0094] Experimental method: Take the fluorescent dye cyt7.5-PLGA nanoparticles (cyt7.5-NP) prepared in Example 11 and resuspend them in sterile physiological saline. Add them to 200 μL of packed red blood cells prepared in Example 9 and incubate at 37°C for 30 minutes. Centrifuge at 100g for 5 minutes, remove the supernatant, and wash three times with sterile physiological saline to obtain cyt7.5-PLGA nanoparticle-red blood cell complex (RBC-cyt7.5-NP).
[0095] Eighteen ICR mice (30±2g) were randomly divided into three groups and intravenously injected with PBS (negative control), Cy7.5-NP and RBC-Cy7.5-NP, respectively. The mice were killed 0.5h and 2h after administration, and the heart, liver, spleen, lung and kidney were imaged and analyzed (excitation wavelength 745nm; emission wavelength 800nm) to analyze the fluorescence distribution intensity of each organ.
[0096] Test results: Fig. 9As shown in the figure, after intravenous injection of Cy7.5-NP, the nanoparticles mainly accumulated in the liver, and no obvious fluorescence signal was observed in the lungs. After intravenous injection of RBC-Cy7.5-NP, the liver was still the main distribution organ of the nanoparticles, but obvious fluorescence signals appeared in the lungs. This indicates that the nanoparticle-erythrocyte combination has the ability of lung-targeted drug delivery and can significantly promote the accumulation of local drugs in the lungs.
Claims
1. A pharmaceutical composition or drug delivery system, comprising: (1) first drug-loaded PLGA nanoparticles and red blood cells, or (2) The second drug-loaded PLGA nanoparticles have their surfaces modified with glycophorin A antibodies.
2. The pharmaceutical composition or drug delivery system of claim 1, wherein the red blood cells are derived from the blood of a subject.
3. The pharmaceutical composition or drug delivery system according to claim 1 or 2, which is administered to a subject by intravenous injection.
4. The pharmaceutical composition or drug delivery system of claim 1 or 2, wherein (1) wherein the first drug-loaded PLGA nanoparticles bind to red blood cells and are loaded on the surface of red blood cells, and / or In (2), the second drug-loaded PLGA nanoparticles bind to red blood cells in the subject's body after intravenous injection and are loaded on the surface of the red blood cells. 5 . The pharmaceutical composition or drug delivery system according to claim 1 , which is a pharmaceutical composition or drug delivery system targeted to the lung.
6. The pharmaceutical composition or drug delivery system according to any one of claims 1 to 5, characterized by one or more of the following features: i) the first drug-loaded PLGA nanoparticles or the second drug-loaded PLGA nanoparticles contain PLGA, and the ratio of lactic acid to glycolic acid is 10:90 to 90:10, preferably 10:90 to 50:50, and more preferably 25:75; ii) the first drug-loaded PLGA nanoparticles or the second drug-loaded PLGA nanoparticles contain PLGA, and the molecular weight thereof is 5000-100000, preferably 10000-50000; iii) the Zeta potential of the first drug-loaded PLGA nanoparticles is -50 to +50 mV, preferably -30 to 0 mV, and more preferably -30 to -15 mV; iv) the Zeta potential of the second drug-loaded PLGA nanoparticles is -50 to +50 mV, preferably -30 to +30 mV, more preferably about 0 mV; v) the particle size of the first drug-loaded PLGA nanoparticles is 5 to 1000 nm, preferably 100 to 500 nm, more preferably 150 to 400 nm; vi) the second drug-loaded PLGA nanoparticles, before being modified with glycophorin A antibody, have a particle size of 5 to 1000 nm, preferably 100 to 500 nm, more preferably 150 to 400 nm; vii) The pharmaceutical composition or drug delivery system further comprises a pharmaceutically acceptable carrier, such as physiological saline.
7. The pharmaceutical composition or drug delivery system according to any one of claims 1 to 5, wherein the drug is a drug for treating lung-related diseases, such as methylprednisolone, pirfenidone or cepharanthin.
8. A method for preparing the pharmaceutical composition or drug delivery system according to any one of claims 1 to 7, include: 1) Add the drug to the organic solution of PLGA and perform ultrasonic emulsification; 2) Optionally, adding the product obtained in 1) to a surfactant solution (e.g., aqueous solution) and stirring; 3) removing the organic solvent from the product obtained in 1) or 2), separating and washing to obtain the first drug-loaded PLGA nanoparticles; 4) combining the first drug-loaded PLGA nanoparticles with red blood cells, or co-incubating the first drug-loaded PLGA nanoparticles with glycophorin A antibodies to obtain second drug-loaded PLGA nanoparticles whose surfaces are modified with glycophorin A antibodies, Preferably, the surfactant solution is selected from the group consisting of: poloxamer (eg, poloxamer P188), polyvinyl alcohol, cetyltrimethylammonium bromide, and any combination thereof.
9. A method for delivering the pharmaceutical composition or drug delivery system according to any one of claims 1 to 7, include: 1) Collecting red blood cells from the subject; 2) co-incubating the first drug-loaded PLGA nanoparticles resuspended in physiological saline with red blood cells, so that the first drug-loaded PLGA nanoparticles bind to the red blood cells and are loaded on the surface of the red blood cells; 3) delivering the product obtained in 2) to the subject intravenously, or The method comprises: directly delivering the second drug-loaded PLGA nanoparticles to a subject intravenously.
10. Use of the pharmaceutical composition or drug delivery system according to any one of claims 1 to 7 in the preparation of a drug for treating acute lung injury, pulmonary fibrosis, and pulmonary tuberculosis.
Citation Information
Patent Citations
Erythrocyte membrane-encapsulated rapamycin nanoparticle and preparation method and application thereof
CN111184700A
Erythrocyte membrane coated drug-loaded nanoparticles / probes and application thereof in diagnosis and treatment of glioblastoma multiforme
CN113499318A
Nanodelivery device for therapeutic loading of circulating erythrocytes
US20160051697A1
Methods and compositions for drug delivery
US20210299272A1
